AdvaMed Responds to Federal Probe on Medtech Imports
The association argues against national security concerns, calling for policies to strengthen domestic manufacturing and exports.
The association argues against national security concerns, calling for policies to strengthen domestic manufacturing and exports.
A coalition of 67 organizations is urging the Centers for Medicare and Medicaid Services to address a multi-year delay between FDA authorization and reimbursement for new medical technologies.
The trade group’s CEO urged lawmakers to adopt a ‘zero for zero’ reciprocal tariff model to prevent supply chain disruptions for medical technologies.
The association argues against national security concerns, calling for policies to strengthen domestic manufacturing and exports.
While pharmaceuticals and certain other products are exempt, industry groups are seeking clarity on how the tariffs may impact sectors like medical technology.
Read MoreAdvaMed has released its Medical Innovation Agenda for the 119th Congress, outlining legislative and policy priorities aimed at accelerating medical technology innovation and expanding patient access to breakthrough treatments.
Read MoreThe organization warns that trade restrictions on medical devices could disrupt patient care and exacerbate existing supply chain challenges.
Read MoreAdvaMed is advocating for an exemption similar to that granted during President Trump’s first term to mitigate risks to patient care and US medtech innovation.
Read MoreAdvaMed applauds the House AI Task Force for calling on CMS to create payment pathways for AI-enabled devices.
Read MoreCaroll H. Neubauer, former CEO of B. Braun of America Inc., received the 2024 AdvaMed Lifetime Achievement Award at The MedTech Conference.
Read More
AdvaMed and ABHI renewed their MOU to enhance collaboration on AI regulation, trade policy, and regulatory convergence, aiming to improve patient access to advanced medical technologies in the U.S. and U.K. medtech markets.